Please login to the form below

Not currently logged in
Email:
Password:

MDD

This page shows the latest MDD news and features for those working in and with pharma, biotech and healthcare.

Sage surges after depression drug gets rapid path to approval

Sage surges after depression drug gets rapid path to approval

SAGE-217 is being tested in post-partum depression (PPD) that affects mother after childbirth as well as major depressive disorder (MDD), for which Sage reported positive phase 2 results last ... results due later this year are positive - and a single,

Latest news

  • Alkermes slumps as FDA turns down depression drug Alkermes slumps as FDA turns down depression drug

    Alkermes was hoping that the massive unmet need in patients with MDD would help sway the FDA. ... Despite the large number of approved agents, the majority of MDD patients treated with standard antidepressants do not achieve adequate relief.

  • Lundbeck partners with 23andMe on first-of-its-kind study Lundbeck partners with 23andMe on first-of-its-kind study

    The US project will involve 25, 000 patients and combine data from genetics, cognitive tests and online surveys to explore how genetics is related to major depressive disorder (MDD), bipolar depression ... Anders Gersel Pedersen, executive VP, research

  • Allergan pushes on with Botox for depression Allergan pushes on with Botox for depression

    Allergan has reported mixed top-line data from a mid-stage trial of its wrinkle treatment Botox in patients with major depressive disorder (MDD), but still thinks it is worth testing ... The specialty pharma group took the decision to test Botox in

  • Takeda pilots Apple Watch depression app Takeda pilots Apple Watch depression app

    Takeda is testing the use of an Apple Watch app for patients with major depressive disorder (MDD). ... Working with UK firm Cambridge Cognition the company is piloting the app to monitor and assess cognitive function in patients with MDD, which affects

  • J&J therapy for suicidal depressives 'a breakthrough', says FDA J&J therapy for suicidal depressives 'a breakthrough', says FDA

    Currently the only approved fast-acting treatments for MDD are transcranial magnetic stimulation and electro-conductive therapy. ... Allergan has an intravenously-administered candidate called rapastinel entering phase III trials as an adjunctive

More from news
Approximately 2 fully matching, plus 24 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Wilmington Healthcare

A heritage to envy Wilmington Healthcare brings together the data intelligence specialisms of Binley’s, NHiS, Wellards and HSJ to create...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics